Kailera makes history with record-breaking $625m IPO

Obesity biotech Kailera Therapeutics has acceptable its sights connected the US nationalist marketplace done an upsized $625m IPO, marking 1 of the largest nationalist offerings successful the sector’s history.

In a 16 April statement, Kailera announced it’d beryllium offering each 39,062,500 of its shares to prospective buyers astatine a terms of $16 per portion – astatine the apical extremity of the suggested terms elaborate successful its S-1 filing – with the institution expected to commence trading connected the Nasdaq nether the ticker “KLRA” connected 17 April.

Underwriters volition besides person 30 days to bargain different 5,859,375 shares astatine $16, leaving different $92.8m up for grabs by the company.

Through this IPO, Kailera expects to unafraid $625m successful gross proceeds, which eclipses the expected $458.7m successful nett proceeds elaborate successful the S-1 form, making it 1 of the largest IPOs successful biotech past since Moderna’s $604m nationalist marketplace debut successful 2018.

With this caller superior successful hand, Kailera hopes to instrumentality different measurement person to the burgeoning obesity marketplace dominated by Eli Lilly and Novo Nordisk – pouring $650m into backing its three-trial, late-stage KaiNETIC programme for pb obesity injectable, ribupatide, into Q2 2028, arsenic per the company’s S-1 filing.

As the oral obesity marketplace picks up steam, the biotech volition besides dedicate $150m to the improvement of its once-daily, ribupatide pill, which volition assistance money Phase III trials involving the therapy.

While ribupatide is presently a cardinal focal constituent for Kailera, the biotech is besides looking to harness these funds to propulsion its different obesity therapies down the pipeline – including tiny molecule glucagon-like peptide 1 receptor agonist (GLP-1RA) pill, KAI-7535, and ‘triple G’ agonist, KAI-4729, which are presently successful mid and early-stage development, respectively.

This IPO comes reasonably soon aft the company’s debut successful October 2024, which saw the Bain-backed biotech marque a splash with a $400m Series A. Since then, the institution has focused connected processing its in-licensed obesity assets from salient Chinese dealmaker, Jiangsu Hengrui Pharmaceuticals, which could spot the biotech vie for glory connected the ex-China obesity market.

While Kailera’s nationalist offering has caused a important disturbance successful the industry, determination person been aggregate different IPOs that person besides been catching the headlines.

This includes precision proteomic specializer Alamar Biosciences, which precocious upsized its 11.25 cardinal stock nationalist offering to $17 to scope a full worth of implicit $191m.

Seaport and Hemab person besides acceptable their sights connected the nationalist market, though some companies are yet to stock further fiscal details connected their offerings.